Mark Vachon has served as a member of our board of directors since July 2014. Mr. Vachon served as an executive vice president sales, integration and operations at Change Healthcare Holdings, Inc. from November 2016 to April 2018. For over 30 years, Mr. Vachon held a variety of leadership positions across the General Electric organization, and was a company officer beginning in 1999 and a member of GE’s Corporate Executive Council. Mr. Vachon was president and chief executive officer of GE Healthcare Americas from 2009 and 2010, and prior to that he was president and chief executive officer of Global Diagnostics Imaging, GE Healthcare, between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was executive vice president and chief financial officer of GE Healthcare. Mr. Vachon serves on the board of trustees of Northeastern University and the board of directors of Numotion, and the Charitable Health and Retirement Trust. Mr. Vachon holds a B.S. in Finance from Northeastern University and an M.A. from Boston College.

John Agwunobi is chief executive officer and chairman of the board of Herbalife Nutrition, a premier global nutrition company that serves customers in 94 countries. Agwunobi is a passionate proponent of Herbalife Nutrition’s mission to improve the nutrition habits of people worldwide, strengthening our communities and providing independent distributors a business opportunity to earn supplemental income. As chief executive officer, he sets the strategy for Herbalife Nutrition, overseeing all aspects of the company’s growth and ensuring that the company continues to be recognized worldwide as a leading nutrition company with a keen focus on initiatives that can positively impact issues affecting global society, including overweight and obesity, healthy aging, and a business opportunity.

Agwunobi previously served as co-president and chief health and nutrition officer, directing the company’s nutrition philosophy. Since joining the company in 2016, Agwunobi has worked closely with Herbalife Nutrition independent distributors and customers, ensuring that the company continuously innovates in the areas of product development, technology, marketing and distributor sales. He also led the Herbalife Nutrition Institute, the Herbalife Nutrition Advisory Board, and the Herbalife Dietetic Advisory Board and worked with the company’s Ph.D.s and scientists to integrate nutrition science into Herbalife Nutrition products.

Agwunobi brings a wealth of experience from both the public and private sectors to his role. Most notably, in the private sector, he served as senior vice president and president of health and wellness for the world’s largest retailer, Walmart, where he led a team of over 65,000 and grew the business from $25 billion to over $30 billion. In the public sector, Agwunobi served as Florida’s secretary of health and later as an admiral in the U.S. Public Health Services Commissioned Corps and the assistant secretary of health for the U.S. Department of Health and Human Services. In these roles, he was responsible for disease prevention and health promotion. He oversaw the Centers for Disease Control, the National Institutes of Health, the Food and Drug Administration, the office of the U.S. Surgeon General, and numerous other public health offices and programs.

Agwunobi has a broad educational background that includes a master's degree in public health from Johns Hopkins University and a master's degree in business administration from Georgetown University. He completed his pediatric residency at Howard University and is currently a licensed physician in Florida and Maryland. He serves on numerous boards, including the U.S. African Development Foundation and bluebird bio.

Charlotte Jones-Burton, MD, MS is Senior Vice President, Product Development and Strategy at Chinook Therapeutics, a clinical-stage biotechnology company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. With more than 20 years of experience as a clinical development leader, internal medicine and nephrology physician and academician, Dr. Jones-Burton is dedicated to creating healthier communities through drug development, patient advocacy and people engagement.

Dr. Jones-Burton earned a medical degree and Master of Science degree in Epidemiology and Preventive Medicine, with a concentration in Clinical Research, from the University of Maryland School of Medicine. Charlotte’s postgraduate training included an internal medicine residency and a nephrology fellowship at the University of Maryland Medical Systems. Immediately prior to her current role at Chinook Therapeutics she was VP, Global Clinical Development Head, Nephrology at Otsuka Pharmaceutical Development & Commercialization, Inc.

Dr. Jones-Burton is active in numerous professional associations and organizations and founded Women of Color in Pharma (WOCIP), a non-profit professional society focused on transforming the pharmaceutical landscape with women of color. In 2021, she was recognized as one of the industry’s top 100 inspiring people by PharmaVoice and awarded the 1st ever Global Icon Award by WOCIP.

Lis Leiderman, M.D., is Chief Financial Officer and Head of Corporate Development at Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders.

Dr. Leiderman has over 20 years of experience in finance, strategy and business development in the life sciences industry. Before joining Decibel, she served as Chief Business Officer for Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases. Prior to Complexa, Dr. Leiderman was Senior Vice President, Head of Corporate Development at Fortress Biotech. Earlier in her career, Dr. Leiderman developed her transaction and capital markets expertise in the healthcare investment banking groups at Nomura, Credit Suisse, Jefferies and UBS. She began her career in medical affairs at AstraZeneca, where she analyzed product and industry trends related to the central nervous system. Dr. Leiderman earned an M.D. from the Sackler School of Medicine at Tel Aviv University, an MBA from The Wharton School at the University of Pennsylvania and a B.A. from The University of Pennsylvania.

Nick Leschly is currently Chief Kairos Officer of 2seventy. Formerly, Nick was chief bluebird at bluebird bio as well as a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

Andrew Obenshain, who joined bluebird in 2016 as head of Europe, now serves as blue’s Chief Executive Officer. Prior to his time at bluebird bio, he was at Shire in Paris, France where he was the general manager of France and Benelux overseeing a portfolio including seven rare disease products. Andrew also spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations, received his MBA from Northwestern University’s Kellogg School of Management, and his B.A. in genetics, cell and developmental biology from Dartmouth College.

Najoh Tita-Reid is Chief Marketing Officer for Logitech, a global manufacturer of computer peripherals, software, and services with headquarters in Switzerland and California. In her role, Ms. Tita-Reid is leading the transformation of the global marketing function and spearheading a strategic, digital-first, and data-driven consumer and customer omnichannel experience. A multi-faceted executive with global marketing expertise, she has a record of strategic and operational ingenuity and transformation across complex organizations and a breadth of experience across the US and Europe.

Prior to her role at Logitech, Ms. Tita-Reid was Global Chief Marketing Officer and Executive Board Member for Hero-AG, a family-run healthy food company, where she developed the organization’s marketing function and brand strategy and built the first global innovation pipeline while overseeing the R&D, innovation, sustainability and quality functions. Ms. Tita-Reid previously held leadership positions at Bayer PLC, where she served as Vice President-Country Division Head for Consumer Care in the UK in Ireland and led the turnaround of the consumer care business; and Merck & Co, Inc where she served as General Manager for Western Europe.

Ms. Tita-Reid spent 19 years at Procter & Gamble where she managed a number of consumer brands in the baby and feminine care categories. At P&G, Ms. Tita-Reid spearheaded multi-cultural marketing strategy across 15 billion-dollar brands and led the multi-brand business unit for Hispanic and African American consumers. During her tenure, Ms. Tita-Reid trained and developed the P&G marketing function on ethnic marketing, and created breakthrough marketing strategies, including “My Black is Beautiful,” which stands as a template for multi-cultural campaigns across industry today.

Ms. Tita-Reid graduated with a Bachelor of Arts from Spelman College and holds an MBA from Fuqua School of Business at Duke University.